Friday, 18 October 2019

Drug Discovery News

  • FDA affirms superiority of Pradaxa over warfarin

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 07 Jun, 2012

    Singapore: US Food and Drug Administration has affirmed Boehringer Ingelheim's Pradaxa 150mg superior in reducing ischemic and hemorrhagic strokes relative to warfarin. This positive change...Read more

  • Sanofi withdraws diabetes drug NDA in the US

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 13 Sep, 2013

    Singapore: Global pharmaceutical company, Sanofi has temporarily withdrawn new drug application (NDA) for lixisenatide in the US and plans to resubmit in 2015.Lixisenatide is approved in Eu...Read more

  • Amgen to acquire Onyx for $10 bn cash

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 26 Aug, 2013

    Singapore: Global biopharmaceutical company Amgen plans to acquire all the outstanding shares of Onyx Pharmaceuticals for $125-per-share, totalling to $10.40 billion, in cash. The deal woul...Read more

  • Effient trial by Daiichi, Lilly fails to meet primary endpoint

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 27 Aug, 2012

    Singapore: The TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarct...Read more

  • Astellas Pharma opens office in Singapore

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 12 Dec, 2013

    Singapore: Astellas Pharma, Japan's pharmaceutical giant with net sales of $10.7 billion and net income of $881 million as at March 31, 2013, has opened its office in Singapore. Astellas w...Read more

  • A*STAR, GSK develop medicines for emerging markets

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 09 Apr, 2013

    Singapore: GlaxoSmithKline (GSK) and A*STAR's Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement to develop new evidence based formulations (E...Read more

  • Aussie firm gets TGA approval for pancreatic cancer drug

    Drug Discovery |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 18 Mar, 2014

    Singapore: Australian biopharmaceutical company, Specialised Therapeutics Australia (STA), has recieved Therapeutic Goods Administration (TGA) approval for ABRAXANE (nanoparticle albumin-bo...Read more

  • Pharmaxis gets grants for fibrotic research

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 08 Jul, 2013

    Singapore: Australian pharmaceutical company Pharmaxis' research projects conducted in conjunction with the University of Sydney have been awarded funding under the Australian Research Coun...Read more

  • Regenerative Therapy for heart failure enters Ph III Trial

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2013

    Singapore: Belgian biotechnology company Cardio3 BioSciences (C3BS) has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congest...Read more

  • Mesoblast to set up stem cell drug plant in Singapore

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 29 May, 2014

    Singapore: Australian regenerative drug company, Mesoblast, is planning to expand its global manufacturing base and the company is in dialogues with Singapore Economic Development Board (ED...Read more

  • Sanford-Burnham, Daiichi form new alliance

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 26 May, 2014

    Singapore: US based Sanford-Burnham Medical Research Institute and Japan's Daiichi Sankyo have formed a three year discovery and pre-clinical drug development partnership for cardiovascular...Read more

  • Boehringer, Eli Lilly to evaluate Trajenta for type 2 diabetes

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 21 Mar, 2013

    Singapore: Boehringer Ingelheim and Eli Lilly have initiated phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albumin...Read more

  • Taiwan firm NCE to get priority review in China

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 21 Mar, 2013

    Singapore: Taiwan Liposome Company's multi-mechanistic anti-cancer new chemical entity Lipotecan has been accepted into the "Green Path" program by the Chinese State Food and Drug Administr...Read more

  • Astrazeneca, China university in research deal

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 19 Dec, 2012

    Singapore: AstraZeneca has signed a research collaboration with Fudan University, one of China's leading academic institutions in the area of cardiovascular diseases (CVDs). CVDs are a lead...Read more

  • Phylogica extends collaboration with Janssen Biotech

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 31 Jan, 2013

    Singapore: Phylogica, a leading Australian peptide drug discovery company, has extended its collaboration with Janssen Biotech and its affiliates to discover, develop and commercialize new ...Read more

  • AstraZeneca, BMS gets positive regulatory feedback on Type 2 diabetes drug

    Drug Discovery |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 29 Nov, 2013

    Singapore: Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided AstraZeneca and Bristol-Myers Squibb a positive opinion recommending app...Read more

  • Regeneron acquires Sanofi eye care antibodies

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 06 May, 2013

    Singapore: US-based Regeneron Pharmaceuticals has acquired exclusive rights to two families of novel antibodies from Sanofi. Regeneron acquired full rights to antibodies targeting the PDGF ...Read more

  • Teva, Xenon enter $335 mn deal for pain drug

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 12 Dec, 2012

    Singapore: Israel-based Teva Pharmaceutical and Canada-based Xenon Pharmaceuticals have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is curre...Read more



Podcast

 

Survey Box

Is Asia-Pacific dominating the global digital transformation in healthcare market?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls